CHEN Linbo,LI Xianpeng,JIANG Hao, et al. Bioinformatic analysis and functional prediction of liver cancer related genes[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(11): 828-832.
Abstract：Objective: To explore the mechanism of liver cancer based on bioinformatics. Methods: Microarray data of Liver cancer related genes were obtained from Gene Expression Omnibus (GEO) database and DEGs were identified using R software. Functional annotations of DEGs were conducted by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG). Then, a protein-protein interaction (PPI) network was constructed to screen hub genes. Finally, the hub genes were verified by GEPIA. Results: A total of 154 differentially expressed genes were identified in liver cancer. GO enrichment analysis revealed that DEGs were mainly involved in telomere organization, DNA replication and regulation of gene expression. KEGG pathway analysis was mainly related to mineral absorption, systemic lupus erythematosus and carbon metabolism in cancer. Ten hub genes including TOP2A, CENPF, ASPM, NEK2, CCNA2, PRC1, MELK, CCNB2, RACGAP1 and NUSAP1 were screened out by constructing PPI network. Subsequent validation in GEPIA database showed that all these 10 genes were up-regulated in liver cancer and associated with the prognosis of liver cancer patients. Conclusion: Bioinformatics can effectively screen and analyze liver cancer related DEGs, which may provide theoretical reference for further exploration of the liver cancer mechanism.
[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] MIKI D, OCHI H, HAYES C N, et al. Hepatocellular carcinoma: towards personalized medicine[J]. Cancer Sci, 2012, 103(5): 846-850.
[3] TINKER A V, BOUSSIOUTAS A, BOWTELL D D. The challenges of gene expression microarrays for the study of human cancer[J]. Cancer Cell, 2006, 9(5): 333-339.
[4] RITCHIE M E, PHIPSON B, WU D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
[5] HUANG D W, SHERMAN B T, LEMPICKI R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1): 44-57.
[6] SZKLARCZYK D, FRANCESCHINI A, WYDER S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life[J]. Nucleic Acids Res, 2015, 43 (Database issue): D447-452.
[7] SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
[8] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
[9] VENKITARAMAN A R. A growing network of cancer-susceptibility genes[J]. N Engl J Med, 2003, 348(19): 1917-1919.
[10] GAO C L, WANG G W, YANG G Q, et al. Karyopherin subunit-alpha 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcino-ma[J]. Oncol Lett, 2018, 15(3): 2815-2820.
[11] GOPINATHAN L, TAN S L, PADMAKUMAR V C, et al. Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis[J]. Cancer Res, 2014, 74(14): 3870-3879.
[12] NITISS J L. DNA topoisomerase II and its growing repertoire of biological functions[J]. Nat Rev Cancer, 2009, 9(5): 327-337.
[13] NITISS J L. Targeting DNA topoisomerase II in cancer che-motherapy[J]. Nat Rev Cancer, 2009, 9(5): 338-350.
[14] LI S, LI X, XU A, et al. Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma[J]. Mol Med Rep, 2018, 17(3): 4720-4728.
[15] CHEN J, RAJASEKARAN M, XIA H, et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway[J]. Gut, 2016, 65(9): 1522-1534.
[16] LIN S Y, PAN H W, LIU S H, et al. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma[J]. Clin Cancer Res, 2008, 14(15): 4814-4820.
[17] SATOW R, SHITASHIGE M, KANAI Y, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma[J]. Clin Cancer Res, 2010, 16(9): 2518-2528.
[18] HE B, YIN J, GONG S, et al. Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis[J]. Medicine (Baltimore), 2017, 96 (25): e6938.
[19] PITNER M K, TALIAFERRO J M, DALBY K N, et al. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies[J]. Expert Opin Ther Targets, 2017, 21(9): 849-859.
[20] GIULIANO C J, LIN A, SMITH J C, et al. MELK expression correlates with tumor mitotic activity but is not required for cancer growth[J]. Elife, 2018, 7. pii: e32838.
[21] FU L, LIU S, WANG H, et al. Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis[J]. Cancer Biomark, 2017, 20(1): 101-106.
[22] WEN S, LIU Y, YANG M, et al. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation[J]. Oncol Rep, 2016, 36(4): 2193-2199.
[23] WANG S M, OOI L L, HUI K M. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma[J]. Clin Cancer Res, 2011, 17(18): 6040-6051.
